Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
Published Online: 2024-08-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Anh Tuan Le•Aurora O'Brate•Barbara Ellers-Lenz•Boon Khaw Lim•Boris M Pfeiffer•Cheng Huang•Chong Kin Liam•Christophe Dooms•Christopher Stroh•Daniel Tan•Dilafruz Juraeva•Egbert F Smit•Ernest Nadal•Filippo de Marinis•Giovanna Finocchiaro•Hidetoshi Hayashi•How Soon Hin•Jialei Wang•Jin-Ji Yang•Jo Raskin•Julien Mazieres•Karin Berghoff•Kosalaram Goteti•Lye Mun Tho•Marie Wislez•Martin Wermke•Masahiro Morise•Nguyen Viet Nhung•Niki Karachaliou•Pei Jye Voon•Puey Ling Chia•Qinghua Zhou•Rainer Strotmann•Svenja Adrian•Tae Min Kim•Terufumi Kato•Valentina Guarneri•Xiuning Le•Yi-Long Wu
